Denali Therapeutics Inc.
DNLI
$19.80
$0.341.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -508.02M | -512.54M | -498.74M | -479.03M | -453.94M |
| Total Depreciation and Amortization | 15.36M | 14.81M | 13.65M | 12.06M | 10.04M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 85.73M | 84.98M | 81.63M | 75.10M | 67.54M |
| Change in Net Operating Assets | -5.41M | 149.00K | 5.69M | 42.26M | 10.81M |
| Cash from Operations | -412.34M | -412.60M | -397.78M | -349.62M | -365.54M |
| Capital Expenditure | -6.89M | -9.50M | -13.07M | -18.33M | -18.84M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 337.88M | 264.78M | 419.79M | 460.88M | 402.02M |
| Cash from Investing | 330.99M | 255.28M | 406.72M | 442.55M | 383.18M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -3.83M | -8.17M | -16.48M | -39.13M | -36.70M |
| Issuance of Common Stock | 944.17M | 925.71M | 9.39M | 14.26M | 16.96M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -528.32M | -728.32M | 0.00 | 0.00 | 0.00 |
| Cash from Financing | 412.02M | 189.22M | -7.09M | -24.87M | -19.73M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 330.68M | 31.90M | 1.86M | 68.06M | -2.10M |